Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

Dose escalation of first in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab

Ruby Meredith, Sui Shen, Patty Bunch, Michael Straughn, Julien Torgue and E. Banaga
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 638;
Ruby Meredith
1Radiation Oncology, University of Alabama Medical, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sui Shen
1Radiation Oncology, University of Alabama Medical, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patty Bunch
1Radiation Oncology, University of Alabama Medical, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Straughn
2Gynecology, University of Alabama Medical, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julien Torgue
3AREVA Med, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Banaga
3AREVA Med, Bethesda, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

638

Objectives To study toxicity, biodistribution, and pharmacokinetics of intra-peritoneal (IP) 212Pb-TCMC-trastuzumab in patients with HER-2 expressing malignancy. This phase I trial provides IP therapy for patients with peritoneal carcinomatosis who have failed standard therapies.

Methods 212Pb-TCMC-trastuzumab was delivered IP <4h after 4mg/kg IV trastuzumab.

Results Four dose levels (7.4, 9.6, 12.6, 16.3 MBq/m2) have shown minimal toxicity at >1 year for 1st group & >2-10 mo for others. Imaging and pharmacokinetics in the 1st cohort (n=3) showed little redistribution of radioactivity out of the peritoneal cavity, no significant uptake in major organs and serum levels <1-23% injected dose of antibody conjugate by 63 hours based on decay corrected values. Non-decay corrected cumulative urinary excretion was <6% in 24h (2.3 half lives). A similar range of serum levels has been observed at 2 and 24h measures in all patients. External radiation dose-rate measurements over the abdomen dropped to 13+/- 4% by 24 h. The 24h data points correlate closely with 212Pb physical decay (T1/2 =10.6 h) but are slightly less when not corrected for urinary loss. Similar loss was noted at 3 other body sites, where the percent of activity was proportional to the distance from the abdomen. Patients tolerated therapy at 7-16 MBq/m2 with minimal, asymptomatic laboratory abnormality (transient Grade 1 in 5/13 patients) and no late cardiac, liver or renal toxicity > 2-12 mo.

Conclusions Four dose levels of IP 212Pb-TCMC-trastuzumab treatment of patients with peritoneal carcinomatosis showed minimal distribution outside the peritoneal cavity and good tolerance with minimal related toxicity.

Research Support AREVA Med, NIH 1UL1RR025777-01

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 55, Issue supplement 1
May 2014
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dose escalation of first in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Dose escalation of first in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab
Ruby Meredith, Sui Shen, Patty Bunch, Michael Straughn, Julien Torgue, E. Banaga
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 638;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Dose escalation of first in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab
Ruby Meredith, Sui Shen, Patty Bunch, Michael Straughn, Julien Torgue, E. Banaga
Journal of Nuclear Medicine May 2014, 55 (supplement 1) 638;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • Comparison of 18F-FDG kinetics between oral uptake and venous injection
  • Homogeneous Sn-117m Colloid Radiosynovectomy Results in Rat Models of Joint Disease
  • Oleanolic acid enhance the radiosensitivity of C6 rat glioma cells by down-regulating HIF-1α expression
Show more Oncology: Basic, Translational & Therapy

Radiopharmaceutical Therapy: Radioimmunotherapy

  • Anti-PSMA labeled liposomes loaded with Actinium-225 for potential antivascular alpha-radiotherapy
  • Treatment of bladder cancer with Bi-213-anti-EGFR-MAb - A pilot study
Show more Radiopharmaceutical Therapy: Radioimmunotherapy

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire